logo
episode-header-image
Nov 2023
26m 30s

The $100 billion opportunity: How anti-o...

GOLDMAN SACHS
About this episode
Goldman Sachs Research’s Chris Shibutani and Jason English explain the business and investor implications of the latest anti-obesity medications and their ripple effects in the healthcare industry and beyond. Learn more about your ad choices. Visit megaphone.fm/adchoices 
Up next
Yesterday
Farallon Capital's Nicolas Giauque on Investing for the Long Term
Managing Partner and CIO Nicolas Giauque of Farallon Capital—a multi-strategy firm founded 40 years ago—talks about the investing opportunities he sees today and his view of the current market environment. This episode was recorded on April 9, 2026. The opinions and views express ... Show More
20m 18s
Apr 16
Apollo's Jim Zelter on the Future of Private Credit
Apollo Global Management President Jim Zelter talks about the unprecedented surge in capital expenditures, the future of private credit, and where he’s seeing investment opportunities around the world. This episode was recorded on March 11, 2026. The opinions and views expressed ... Show More
37m 34s
Apr 14
Why Aren’t Investors More Worried?
Goldman Sachs Research’s Dominic Wilson discusses the impact of the Iran conflict—including the US blockade of the Strait of Hormuz—on global markets. In discussion with Exchanges Host Allison Nathan, he explores the market reactions, risks, and the outlook for equities, rates, c ... Show More
19m 32s
Recommended Episodes
Feb 2024
The Big Business Behind Weight Loss Drugs
It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ... Show More
33m 54s
Mar 2023
Antibiotics: How to fix a broken market
Antibiotics stopped providing big gains for pharmaceutical companies decades ago, but as bacteria become more resistant to drugs, the world needs new classes of antibiotics to be discovered if we want to prevent the next global health crisis.Dr Tina Joshi, Associate Professor of ... Show More
18m 23s
Jan 2024
Will Anti-Obesity Drugs Disrupt the MedTech Industry?
tail spinning
3m 32s
Sep 2023
2. The drug behind Europe's most valuable company
How much harm has been done by decades of governments investing too little? Is buy-now-pay-later causing misery or joy for young shoppers? Are supermarkets cutting prices fast enough? Is Novo Nordisk’s anti obesity wonder drug Semaglutide the most important pharmaceutical discove ... Show More
56m 39s
Jan 2023
Terence Flynn: The Next Blockbuster for Pharma?
tail spinning
3m 12s
Dec 2020
Chautauqua's Beitner: Optimism is excessive relative to long-term impacts from pandemic
Brian Beitner of Chautauqua Capital Management says that investors are risk-on right now -- despite a market and global economy that could have trouble shaking off the impacts of coronavirus -- at a time when they likely should be risk-off, meaning more conservative and fearful o ... Show More
59m 10s
May 2018
Antitrust and Big Tech, and Is Corporate Lobbying A Good or Bad Thing?
In this episode, Youngme, Mihir and Felix discuss antitrust and whether we should be concerned about the size of the big tech companies; debate the propriety of corporate lobbying; and offer their After Hours Picks for the week. Hosted on Acast. See acast.com/privacy for more inf ... Show More
31m 36s
Jan 2024
Episode 104: Jewelry, Insurance and the Holidays
Dustin Lemick, founder and CEO of insurance technology company BriteCo, shares his insights on the recent festive shopping season in a conversation we recorded on December 20. Plus: How lab-grown pricing impacts insurance.  
35m 40s